600252 Guangxi Wuzhou Zhongheng Group
- 2.35
- +0.02+0.86%
Guangxi Wuzhou Zhongheng Group News
Guangxi Wuzhou Zhongheng Group (600252.SH) received a cash dividend of 9.8192 million yuan from Sealand Securities in 2023.
Guangxi Wuzhou Zhongheng Group (600252.SH) issued an announcement that the company recently received a letter of inquiry from Sealand Securities Co., Ltd. (referred to as "...")
Guangxi Wuzhou Zhongheng Group (600252.SH): Has repurchased 1.2355% of the company's shares.
Guangxi Wuzhou Zhongheng Group (600252.SH) announced on June 3 that as of May 31, 2024, the company has repurchased a total of 42,644,400 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 1.2355% of the total share capital of the company, with the highest repurchase price of 2.52 yuan/share, the lowest price of 2.20 yuan/share, and the total amount of funds paid is RMB 101,336,744.00 (excluding stamp duty, transaction commission and other transaction fees).
Zhongheng Group (600252.SH): 1.0013% shares have been repurchased cumulatively
Gelonghui, May 29丨Zhonghui Group (600252.SH) announced that as of May 28, 2024, the company had repurchased a total of 35.59 million shares through the Shanghai Stock Exchange trading system, accounting for 1.0013% of the company's total share capital of 3,451,489,454 shares, an increase of 0.6513% compared with the previous disclosure. The highest price of the repurchase transaction was 2.52 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 82.0693 million (excluding stamp duty and transaction commissions) etc. transaction fees).
Zhongheng Group (600252.SH): The subsidiary plans to cooperate with Hongyi Group to establish a healthcare equity investment fund
Gelonghui, May 21丨Zhongheng Group (600252.SH) announced that in order to achieve Zhongheng Group's endogenous and epitaxial two-wheel drive development, promote Zhongheng Group to become a leading pharmaceutical company for clinical solutions in the cardiovascular field and a comprehensive benchmark enterprise in the medical and health industry, accelerate mergers and acquisitions and improve capital operation efficiency. Zhongheng Yixin, a wholly-owned subsidiary of Zhongheng Group, plans to establish a healthcare equity investment fund with Hongyi Group. The investment direction is mainly mid-stage biomedical projects, including innovative medical devices, accurate diagnosis, digital medicine, etc. The total amount raised by this fund is 70
Zhongheng Group (600252.SH): Total share repurchase capital to be adjusted to 200 million yuan to 300 million yuan
Gelonghui Group (600252.SH) announced on May 21丨Zhongheng Group () announced that the total capital to repurchase shares will be adjusted from “not less than RMB 150,000 (inclusive) and no more than RMB 200,000 (inclusive)” to “not less than RMB 200,000 (inclusive) and no more than RMB 300,000 (inclusive)”. The use of share buybacks was changed from “to implement equity incentives” to “to implement equity incentives or employee stock ownership plans.”
Zhongheng Group (600252.SH): A total of 12.103 million shares have been repurchased
Gelonghui Group (600252.SH) announced on May 7, 2024, that as of April 30, 2024, the company had repurchased 12,103,000 shares of the company through centralized bidding transactions, accounting for 0.35% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.44 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 27,023,304.00 (excluding transaction fees such as stamp duty and transaction fees).
Why Investors Shouldn't Be Surprised By Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
With a price-to-sales (or "P/S") ratio of 2.6x Guangxi Wuzhou Zhongheng Group Co.,Ltd (SHSE:600252) may be sending bullish signals at the moment, given that almost half of all the Pharmaceuticals comp
Zhongheng Group (600252.SH): Net profit of 54.711,200 yuan in the first quarter
Gelonghui, April 29丨Zhonghui Group (600252.SH) released its report for the first quarter of 2024, achieving operating income of 806 million yuan, an increase of 20.34% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of RMB 26.0875 million, an increase of 1461.09% over the previous year; net profit attributable to shareholders of listed companies was 54.7112 million yuan, with basic earnings per share of 0.016 yuan.
Zhongheng Group (600252.SH): Initial repurchase of 0.21% of shares
Gelonghui Group (600252.SH) announced on April 16, 2024, that on April 16, 2024, the company repurchased 7,168,600 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.21% of the company's total share capital of 3,451,489,454 shares. The highest price of the repurchase transaction was 2.25 yuan/share, the lowest price was 2.20 yuan/share, and the total amount of capital paid was RMB 15,959,328.00 (excluding transaction fees such as stamp duty and transaction fees).
We Like The Quality Of Guangxi Wuzhou Zhongheng GroupLtd's (SHSE:600252) Earnings
Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. Our analysis suggests that shareholders might b
Zhongheng Group (600252.SH): Shares have not been repurchased
Gelonghui, April 2, 丨 Zhongheng Group (600252.SH) announced that as of March 31, 2024, the company had not repurchased shares.
Zhongheng Group (600252.SH) announced its 2023 annual results, with net profit of 84.31 million yuan, an increase of 6.69% over the previous year. It plans to distribute 0.1 yuan to 10
Zhongheng Group (600252.SH) disclosed its 2023 annual report, and the company achieved revenue of 30 in 2023...
Zhongheng Group (600252.SH) Holdings Sun Company obtained 2 medical device registration certificates
Zhongheng Group (600252.SH) announced that recently, the company holds Sun Company Hainan Laimei Medical Devices Co., Ltd. (...
Zhongheng Group (600252.SH): Omeprazole magnesium enteric tablets obtained drug registration certificate
On March 19, Ge Longhui Group (600252.SH) announced that its holding subsidiary Chongqing Laimei Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for 20 mg omeprazole magnesium enteric tablets approved and issued by the State Drug Administration. Omeprazole magnesium enteric tablets are mainly used to treat duodenal ulcers, stomach ulcers, and reflux esophagitis; use in combination with antibiotics to treat duodenal ulcers caused by Helicobacter pylori; treat peptic ulcers or gastroduodenal erosions associated with nonsteroidal anti-inflammatory drugs; prevent peptic ulcers, gastroduodenal erosion or dyspepsia caused by nonsteroidal anti-inflammatory drugs
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug
China's National Medical Products Administration approved the application of Guangxi Wuzhou Zhongheng Group's (SHA:600252) unit, Chongqing Lummy Pharmaceutical (SHE:300006), to increase the dosage of
Shareholders 22% Loss in Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Partly Attributable to the Company's Decline in Earnings Over Past Five Years
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to find enough winners to more than offset the losers At this point some shareholder
Zhongheng Group (600252.SH) plans to spend 150 million yuan to 200 million yuan to repurchase shares at a repurchase price of no more than 3.34 yuan/share
Zhongheng Group (600252.SH) issued an announcement that the company plans to use its own funds to buy back the public through centralized bidding transactions...
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) price-to-sales (or "P/S") ratio of 2.7x might make it look like a buy right now compared to the Pharmaceuticals industry in China, where around h
Zhongheng Group (600252.SH): There are currently no proprietary Chinese medicines for mycoplasma pneumonia
Gelonghui, December 18|Zhongheng Group (600252.SH) stated on an interactive platform that the company currently has no proprietary Chinese medicine for mycoplasma pneumonia.
Zhongheng Group (600252.SH): Holding subsidiary Shuangqian Industrial plans to carry out shareholding system reform
On December 12, Gelonghui Group (600252.SH) announced that in order to further optimize the organizational structure and improve the level of governance, Guangxi Wuzhou Shuangqian Industrial Co., Ltd. (“Double Money Industrial” for short), a holding subsidiary of the company, plans to carry out a shareholding system reform and overall change to a limited liability company. The method adopted for this restructuring is to change the entire company to a limited company, and the name after the restructuring is proposed to be “Guangxi Shuangqian Health Industry Co., Ltd.” The company limited company after the overall change undertakes the claims and liabilities of the original limited company. Each sponsor holds shares in a joint stock company in accordance with the proportion of shares originally held in the limited company.
Analysis
Price Target
No Data
